Serum Urate Goals Tied to Lower CV Risk
Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients
By
Andrea Surnit
May 11, 2026
Clinical Scorecard: Serum Urate Goals Tied to Lower CV Risk
At a Glance
Category Detail
Condition Gout Key Mechanisms Achieving serum urate targets is associated with lower cardiovascular risk. Target Population Adults with newly diagnosed gout and pretreatment serum urate levels greater than 6 mg/dL. Care Setting Outpatient setting with urate-lowering therapy.
Key Highlights
27% of patients achieved serum urate levels lower than 6 mg/dL within 12 months. Patients achieving targets had a 5-year hazard ratio of 0.91 for major adverse cardiovascular events. Stronger association observed in patients achieving levels lower than 5 mg/dL (hazard ratio 0.77). 99% of patients received allopurinol, limiting generalizability to other therapies. Findings suggest a link between gout flares, systemic inflammation, and cardiovascular risk. Guideline-Based Recommendations
Diagnosis
Monitor serum urate levels in patients with gout. Management
Aim for serum urate levels lower than 6 mg/dL with urate-lowering therapy. Monitoring & Follow-up
Regularly assess serum urate levels and cardiovascular risk factors. Risks
Consider potential residual confounding and adherence issues in treatment outcomes. Patient & Prescribing Data
Adults with newly diagnosed gout.
Focus on achieving serum urate targets to potentially lower cardiovascular risks.
Clinical Best Practices
Encourage adherence to urate-lowering therapy. Implement comprehensive cardiovascular risk management for patients with gout. Address gaps between guideline recommendations and routine care. Related Resources & Content
